{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:12:40Z","timestamp":1777983160986,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7560","license":[{"start":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T00:00:00Z","timestamp":1432512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T00:00:00Z","timestamp":1432512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2015,7,16]]},"DOI":"10.1038\/nature14430","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T13:39:20Z","timestamp":1432301960000},"page":"352-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":317,"title":["Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment"],"prefix":"10.1038","volume":"523","author":[{"given":"E. M.","family":"Alexandrova","sequence":"first","affiliation":[]},{"given":"A. R.","family":"Yallowitz","sequence":"additional","affiliation":[]},{"given":"D.","family":"Li","sequence":"additional","affiliation":[]},{"given":"S.","family":"Xu","sequence":"additional","affiliation":[]},{"given":"R.","family":"Schulz","sequence":"additional","affiliation":[]},{"given":"D. A.","family":"Proia","sequence":"additional","affiliation":[]},{"given":"G.","family":"Lozano","sequence":"additional","affiliation":[]},{"given":"M.","family":"Dobbelstein","sequence":"additional","affiliation":[]},{"given":"U. M.","family":"Moll","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,5,25]]},"reference":[{"key":"BFnature14430_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/path.2748","volume":"222","author":"B Doyle","year":"2010","unstructured":"Doyle, B. et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 222, 129\u2013137 (2010)","journal-title":"J. Pathol."},{"key":"BFnature14430_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/cdd.2013.17","volume":"20","author":"W Hanel","year":"2013","unstructured":"Hanel, W. et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20, 898\u2013909 (2013)","journal-title":"Cell Death Differ."},{"key":"BFnature14430_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","volume":"119","author":"GA Lang","year":"2004","unstructured":"Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861\u2013872 (2004)","journal-title":"Cell"},{"key":"BFnature14430_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","volume":"107","author":"JP Morton","year":"2010","unstructured":"Morton, J. P. et al. Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 246\u2013251 (2010)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature14430_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847\u2013860 (2004)","journal-title":"Cell"},{"key":"BFnature14430_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc2693","volume":"9","author":"R Brosh","year":"2009","unstructured":"Brosh, R. & Rotter, V. When mutants gain new powers: news from the mutant p53 field. Nature Rev. Cancer 9, 701\u2013713 (2009)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14430_CR7","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1101\/gad.1662908","volume":"22","author":"T Terzian","year":"2008","unstructured":"Terzian, T. et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 22, 1337\u20131344 (2008)","journal-title":"Genes Dev."},{"key":"BFnature14430_CR8","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-11-0459","volume":"71","author":"YA Suh","year":"2011","unstructured":"Suh, Y. A. et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 71, 7168\u20137175 (2011)","journal-title":"Cancer Res."},{"key":"BFnature14430_CR9","doi-asserted-by":"publisher","first-page":"8379","DOI":"10.1073\/pnas.93.16.8379","volume":"93","author":"MV Blagosklonny","year":"1996","unstructured":"Blagosklonny, M. V., Toretsky, J., Bohen, S. & Neckers, L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl Acad. Sci. USA 93, 8379\u20138383 (1996)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature14430_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1128\/MCB.18.3.1517","volume":"18","author":"L Whitesell","year":"1998","unstructured":"Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D. & Cook, P. H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol. 18, 1517\u20131524 (1998)","journal-title":"Mol. Cell. Biol."},{"key":"BFnature14430_CR11","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","volume":"18","author":"D Li","year":"2011","unstructured":"Li, D., Marchenko, N. D. & Moll, U. M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 18, 1904\u20131913 (2011)","journal-title":"Cell Death Differ."},{"key":"BFnature14430_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","volume":"9","author":"D Li","year":"2011","unstructured":"Li, D. et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 9, 577\u2013588 (2011)","journal-title":"Mol. Cancer Res."},{"key":"BFnature14430_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/jmg.2008.057570","volume":"45","author":"G Bougeard","year":"2008","unstructured":"Bougeard, G. et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J. Med. Genet. 45, 535\u2013538 (2008)","journal-title":"J. Med. Genet."},{"key":"BFnature14430_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/humu.22254","volume":"34","author":"Y Zerdoumi","year":"2013","unstructured":"Zerdoumi, Y. et al. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum. Mutat. 34, 453\u2013461 (2013)","journal-title":"Hum. Mutat."},{"key":"BFnature14430_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304\u2013317 (2014)","journal-title":"Cancer Cell"},{"key":"BFnature14430_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","volume":"157","author":"S Weissmueller","year":"2014","unstructured":"Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157, 382\u2013394 (2014)","journal-title":"Cell"},{"key":"BFnature14430_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nature Rev. Cancer 10, 537\u2013549 (2010)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14430_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nature Rev. Cancer 5, 761\u2013772 (2005)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature14430_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.cell.2007.07.020","volume":"130","author":"C Dai","year":"2007","unstructured":"Dai, C., Whitesell, L., Rogers, A. B. & Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130, 1005\u20131018 (2007)","journal-title":"Cell"},{"key":"BFnature14430_CR20","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1038\/sj.onc.1210317","volume":"26","author":"JN Min","year":"2007","unstructured":"Min, J. N., Huang, L., Zimonjic, D. B., Moskophidis, D. & Mivechi, N. F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 26, 5086\u20135097 (2007)","journal-title":"Oncogene"},{"key":"BFnature14430_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/CAD.0000000000000040","volume":"25","author":"M Slingerland","year":"2014","unstructured":"Slingerland, M., Guchelaar, H. J. & Gelderblom, H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25, 140\u2013149 (2014)","journal-title":"Anticancer Drugs"},{"key":"BFnature14430_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","volume":"94","author":"J Zou","year":"1998","unstructured":"Zou, J., Guo, Y., Guettouche, T., Smith, D. F. & Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471\u2013480 (1998)","journal-title":"Cell"},{"key":"BFnature14430_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012)","journal-title":"Nature"},{"key":"BFnature14430_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bcp.2011.12.017","volume":"83","author":"D Siegel","year":"2012","unstructured":"Siegel, D., Yan, C. & Ross, D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem. Pharmacol. 83, 1033\u20131040 (2012)","journal-title":"Biochem. Pharmacol."},{"key":"BFnature14430_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","volume":"74","author":"DA Proia","year":"2014","unstructured":"Proia, D. A. & Bates, R. C. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res. 74, 1294\u20131300 (2014)","journal-title":"Cancer Res."},{"key":"BFnature14430_CR26","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","volume":"19","author":"MA Socinski","year":"2013","unstructured":"Socinski, M. A. et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res. 19, 3068\u20133077 (2013)","journal-title":"Clin. Cancer Res."},{"key":"BFnature14430_CR27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1096\/fasebj.7.10.8344491","volume":"7","author":"M Harvey","year":"1993","unstructured":"Harvey, M. et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7, 938\u2013943 (1993)","journal-title":"FASEB J."},{"key":"BFnature14430_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","volume":"4","author":"T Jacks","year":"1994","unstructured":"Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1\u20137 (1994)","journal-title":"Curr. Biol."},{"key":"BFnature14430_CR29","doi-asserted-by":"publisher","first-page":"e1411","DOI":"10.1038\/cddis.2014.378","volume":"5","author":"H Landmann","year":"2014","unstructured":"Landmann, H. et al. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death Dis. 5, e1411 (2014)","journal-title":"Cell Death Dis."},{"key":"BFnature14430_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd4236","volume":"13","author":"KH Khoo","year":"2014","unstructured":"Khoo, K. H., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Rev. Drug Discov. 13, 217\u2013236 (2014)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature14430_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05541","volume":"445","author":"A Ventura","year":"2007","unstructured":"Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661\u2013665 (2007)","journal-title":"Nature"},{"key":"BFnature14430_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nrd4201","volume":"13","author":"M Dobbelstein","year":"2014","unstructured":"Dobbelstein, M. & Moll, U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nature Rev. Drug Discov. 13, 179\u2013196 (2014)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature14430_CR33","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2741\/4050","volume":"17","author":"M Gorska","year":"2012","unstructured":"Gorska, M. et al. Geldanamycin and its derivatives as Hsp90 inhibitors. Front. Biosci. 17, 2269\u20132277 (2012)","journal-title":"Front. Biosci."},{"key":"BFnature14430_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1476-4598-9-49","volume":"9","author":"A Hrzenjak","year":"2010","unstructured":"Hrzenjak, A. et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol. Cancer 9, 49 (2010)","journal-title":"Mol. Cancer"},{"key":"BFnature14430_CR35","doi-asserted-by":"publisher","first-page":"e18552","DOI":"10.1371\/journal.pone.0018552","volume":"6","author":"DA Proia","year":"2011","unstructured":"Proia, D. A. et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling. PLoS ONE 6, e18552 (2011)","journal-title":"PLoS ONE"},{"key":"BFnature14430_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","volume":"11","author":"W Ying","year":"2012","unstructured":"Ying, W. et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 11, 475\u2013484 (2012)","journal-title":"Mol. Cancer Ther."}],"updated-by":[{"DOI":"10.1038\/nature15720","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature14430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature14430","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature14430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:31:13Z","timestamp":1684434673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature14430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,25]]},"references-count":36,"journal-issue":{"issue":"7560","published-print":{"date-parts":[[2015,7,16]]}},"alternative-id":["BFnature14430"],"URL":"https:\/\/doi.org\/10.1038\/nature14430","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nature15720","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,25]]},"assertion":[{"value":"20 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Competing Interests: D.A.P. is employed by Synta Pharmaceuticals, a company that studies ganetespib, one of the drugs used in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}